ZA200006047B - Smilagenin and anzurogenin-D for the treatment of Alzheimer's disease. - Google Patents
Smilagenin and anzurogenin-D for the treatment of Alzheimer's disease. Download PDFInfo
- Publication number
- ZA200006047B ZA200006047B ZA200006047A ZA200006047A ZA200006047B ZA 200006047 B ZA200006047 B ZA 200006047B ZA 200006047 A ZA200006047 A ZA 200006047A ZA 200006047 A ZA200006047 A ZA 200006047A ZA 200006047 B ZA200006047 B ZA 200006047B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- substance
- treatment
- anzurogenin
- smilagenin
- Prior art date
Links
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 title claims description 46
- 238000011282 treatment Methods 0.000 title claims description 30
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 26
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 title claims description 26
- 229950002323 smilagenin Drugs 0.000 title claims description 23
- JYLQYOXTEAKERB-UHFFFAOYSA-N Anzurogenin D Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4(O)C(O)CC3C2C2)C)C2OC11CCC(C)CO1 JYLQYOXTEAKERB-UHFFFAOYSA-N 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 17
- 230000003920 cognitive function Effects 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 10
- 230000007812 deficiency Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 241000605422 Asparagus asparagoides Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 235000012044 Yucca brevifolia Nutrition 0.000 claims description 4
- 244000193174 agave Species 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000605447 Anemarrhena Species 0.000 claims description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 3
- 239000001653 FEMA 3120 Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 235000004552 Yucca aloifolia Nutrition 0.000 claims description 3
- 235000017049 Yucca glauca Nutrition 0.000 claims description 3
- 229930191283 anemarrhena Natural products 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 241001532059 Yucca Species 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 42
- 108020003175 receptors Proteins 0.000 description 42
- 230000000694 effects Effects 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 32
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 19
- 229960004373 acetylcholine Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 14
- 230000027455 binding Effects 0.000 description 12
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 11
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 11
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 9
- 108091006027 G proteins Proteins 0.000 description 9
- 102000030782 GTP binding Human genes 0.000 description 9
- 108091000058 GTP-Binding Proteins 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 7
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 7
- 230000003518 presynaptic effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 6
- 240000002493 Smilax officinalis Species 0.000 description 6
- 235000008981 Smilax officinalis Nutrition 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001713 cholinergic effect Effects 0.000 description 6
- 230000001242 postsynaptic effect Effects 0.000 description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 229960002715 nicotine Drugs 0.000 description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 244000116042 Yucca brevifolia Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 241000234427 Asparagus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010056557 Gulf war syndrome Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 101100463797 Rattus norvegicus Pgrmc1 gene Proteins 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 240000009241 Smilax aspera Species 0.000 description 1
- 235000003531 Smilax aspera Nutrition 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 235000004584 Yucca mohavensis Nutrition 0.000 description 1
- 244000110633 Yucca schidigera Species 0.000 description 1
- 235000006012 Yucca schidigera Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- JSDSJUPEGNNVNX-NERVNPJOSA-N furospirostane Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CCC(C)(C)O1 JSDSJUPEGNNVNX-NERVNPJOSA-N 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 201000010076 persian gulf syndrome Diseases 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- JVKYZPBMZPJNAJ-OQFNDJACSA-N solanidine group Chemical group [C@H]12CC[C@H](C)CN1[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C JVKYZPBMZPJNAJ-OQFNDJACSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003565 tacrine hydrochloride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KOZCINYDCJVLDW-YOGGMVBGSA-N tomatanine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)C11CCC(C)CN1 KOZCINYDCJVLDW-YOGGMVBGSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SMILAGENIN AND ANZUROGENIN-D AND THEIR USE
The present invention relates to smilagenin and anzurogenin-D and their use in treating cognitive disfunction and allied conditions; and to compositions for use im such treatments. The invention is also concerned with the treatment of conditions that are characterised by a deficiency in the number or function of membrane-bound receptors. In the following, the present invention will be described principally with reference to the treatment of Alzheimer's disease (AD) and senile dementia of the Alzheimer's type (SDAT), where deficiencies in a number of receptor types have been demonstrated. However, it is to be understood that the present invention relates generally to the treatment of conditions attributable to intrinsic pathological conditions and/or exposure to adverse environmental conditions these conditions being characterised by a deficiency in the number or function of membrane-bound receptors or a deficiency in transmission at the junctions between neurones or at the junctions of neurones and effector cells.
Conditions of the type mentioned above include Parkinson's disease,
Lewi body dementia, postural hypotension, autism, chronic fatigue syndrome,
Myasthenia Gravis, Lambert Eaton disease, diseases and problems associated with Gulf War Syndrome, occupational exposure to organophosphorus compounds and problems associated with ageing.
Alzheimer's disease (AD) and senile dementia of the Alzheimer's type (SDAT) are grave and growing problems in all societies where, because of an increase in life expectancy and control of adventitious disease, the demographic profile is increasingly extending towards a more aged population. Agents which can treat, or help in the management of, AD/SDAT are urgently required.
Age—associated memory impairment (AAMI) is a characteristic of older patients who, while being psychologically and physically normal, complain of memory loss. It is a poorly defined syndrome, but agents which are effective in treatment of AD/SDAT may also be of value in these patients. - z= Research into AD/SDAT is being carried out by traditional and
SEE 5 “+ conventional medical research methods and disciplines. In conventional i “medicine, there are several approaches to the treatment of AD/SDAT. It is known that the biochemical processes subserving memory in the cerebral cortex ~ are (at least in part) cholinergically-mediated. Those skilled in the art will know that "cholinergically mediated" mechanisms may be directly attributable to : 10 acetylcholine acting on receptors, and these are direct effects. Other, clinically : useful effects may also be caused by modulation of release of acetylcholine = “= from pre-synaptic nerve endings or inhibition of enzymes that destroy : + acetylcholine. These modulating factors may be exerted through neurones <> where the mediator is non—cholinergic; these are referred to as indirect effects. : 15 = Some attempts at treatment have focussed on the role of other mediators such as ” = S5-hydroxytryptamine, which is a mediator in other areas of brain, such as the : ~ mid-brain nuclei. However, since fibres from these areas are projected forward into the cerebral cortex where the primary transmitter is acetylcholine, attention has focussed on the management of this mediator in the search for appropriate therapeutic agents.
Cholinergic strategies for the treatment of AD/SDAT have been directed at several points along the pathway of formation, synaptic release and removal of released acetylcholine.
One approach involves treatment with high doses of lecithin and other precursors of acetylcholine. This is of limited use in producing sustained improvements in cognitive performance. "Another approach involves the use of vegetable drugs such as Polygalae root extract, which has been shown to enhance choline—acetylcholine transferase a (CAT) activity and nerve growth factor (NGF) secretion in brain. Oral administration of NGF has no effect on central nervous system neurons because it is a high molecular weight protein that cannot pass through the blood-brain barricr. However, agents which can pass through the blood-brain barrier and have a stimulating effect on NGF synthesis in the central nervous system have been proposed for the improvement of memory-related behaviour.
The results of a third clinical approach, which uses cholinesterase inhibitors such as tacrine hydrochloride, have been marginally more positive than the above. Substances obtained from plants used in Chinese and Western medicine, for example huperzine, galanthamine, and physostigmine have all been shown to be of some — although limited — benefit in the treatment of
AD/SDAT in clinical studies and also in laboratory models. All of these substances are inhibitors of acetylcholine esterase (AChE). In patients with " 15 AD/SDAT, there may be reduced synthesis of acetylcholine (ACh), reduced efficiency in release of ACh from presynaptic stores, and a decrease in the number or function of postsynaptic (M;) receptors. Reductions in pre-synaptic
M,, receptors have also been shown. The beneficial effect of AChE inhibitors is attributed to enhancement of acetylcholine levels at synapses in brain by slowing down the destruction of released transmitter.
Compositions which modulate cholinergic function are known to affect memory and recall. For example, nicotine stimulates nicotinic acetylcholine receptors, and the short lived memory enhancing effects of cigarette smoking are thought to be due to the effect of nicotine. Scopolamine, an antagonist of acetylcholine, will produce amnesia and impaired cognitive function manifesting in psychomotor tests as a prolongation of simple reaction times, possibly as a result of impaired attention, and is used for this purpose as an adjunctive analgesic treatment. The amnesic effect of scopolamine can be antagonised by nicotine. :
Le a ~4-
There are two families of nicotinic receptor subtypes (a and 8), and each includes four subgroups which differ in ligand specificity. The role of nicotinic - receptors in the CNS is not well understood at the molecular level. It is : - possible that agents binding to nicotinic receptors may modify the rate of -- turnover at muscarinic receptor sites in brain. Nicotinic receptors are “ligand-gated ion channels, and their activation causes a rapid (millisecond) ~ increase in cellular permeability to Na* and Ca**, depolarisation and excitation. : Another class of cholinergic receptors can be stimulated by muscarine.
Such muscarinic (M) receptors are G protein-coupled receptors. Responses of muscarinic receptors are slower; they may be excitatory or inhibitory. They are “ % not necessarily linked to changes in ion permeability. Five types of muscarinic receptors have been detected by cholinergic receptor cloning, and are designated 5 as m,-m,. Pharmacological effects are associated with four of the cloned ~ 15 receptors and they are designated as M,;-M, based on pharmacological specificity.
Using specific receptor proteins and monoclonal antibodies, it has been - possible to further localisc muscarinic receptors in brain as m, (postsynaptic) and m, (presynaptic). In heart, M, receptors are postsynaptic. Presynaptic muscarinic receptors are thought to be inhibitory, the binding of ACh to these receptors attenuating the release of further ACh to provide a negative feedback mechanism for Ach release. Selective M, receptor antagonists which are preferentially distributed to the brain may therefore be useful in treating
Alzheimer's disease.
It is known that, in disease states such as AD/SDAT, there is general neuronal loss and deficits in cholinergic nerve function. It has been speculated that the high affinity nicotinic binding sites in the remaining cholinergic neurons might be converted to low affinity binding sites in treating such diseases, thereby sustaining transmitter release. By lowering the affinity of the nicotinic
* wos PCT/GB99/00960 binding sites, a quick desensitising process is avoided.
Agonist activation at nicotinic receptors in brain has rapid onset and offset. A decreased affinity of the nicotinic receptors will reduce the desensitisation process. Schwarz R.D. et al (J. Neuro Chem 42, (1984), 1495-8) have shown that nicotine binding sites are presynaptically located on cholinergic (and also S5-hydroxytryptaminergic and catecholaminergic) axon terminals. A change in high affinity binding sites on AD/SDAT may also induce a change in the modulatory effect the nicotinic binding sites may have on other transmitter systems.
Presynaptic cholinergic mechanisms are also under inhibitory control by
GABAergic neurons and this inhibition is thought to be intensified in
AD/SDAT. Removal or reduction of this inhibition intensifies presynaptic v 15 cortical cholinergic activity and cnhances cognitive processing.
The interactions of interneuronal fibres innervated by nicotine (reducing binding affinity), and dis—inhibition of GABAergic fibres both have a : presynaptic locus.
This is a simplistic model of central transmission, but provides a framework for understanding the attempts which have been made to increase the effective concentration of acetylcholine in central synapses. This further illustrates the concept of direct and indirect action. There are disadvantages attaching to the three conventional therapeutic approaches to AD/SDAT treatment mentioned above: ACh precursor supplementation, agonist replacement and acetylcholine esterase inhibition. These treatments may result in a short~term increase in the availability of ACh which may activate feedback mechanisms resulting in the desensitisation of postsynaptic receptors. On theoretical grounds, long term benefits would not be predicted and when treatment is interrupted, any benefits in management of AD/SDAT and AAMI disappear and the condition may even be aggravated.
It has been shown that a compound with M; agonist and M,/M, + antagonist activity improved cognitive performance in SDAT patients (Sramak et . § ~~ al, Life Sciences vol. 2, No. 3, 195-202, 1997). However, this compound oo ¥ causes unacceptable cholinergic side effects, such as fatigue, diarrhoea and nausea. oo A more radical approach to AD/SDAT and AAMI aims to increase the - 10 "number of postsynaptic (M,) receptors, in brain. It is known from Chinese : Patent No. CN1096031A, that sarsasapogenin (SaG) can up-regulate M, o “cholinergic receptors and also down-regulate (i.e. move towards normal levels : “ of) p—adrenergic receptors, the number of which may be pathologically-raised - in AD/SDAT. i Patent applications have been published which claim the usefulness of a number of steroid sapogenins having spirostane, furo—spirostane, spirosolane or solanidine structures in the treatment of diseases including SDAT. Two patent publications are of particular relevance here: Chinese patent publication No
CN1096031A claims the use of the spirostane sapogenin, sarsasapogenin, in the treatment of SDAT. The disclosure in this document, however, is brief. The other document of relevance is patent publication DE 4303214A1 which claims the use of a very wide range of saponins and sapogenins in the treatment of a whole range of diseases that the inventors consider to be of viral origin. This disclosure is however of dubious value in that it is well recognised that there is no infective elcment to a very large number of the conditions that are characterised by deficient synaptic transmission and thus the basic premise of the alleged invention is flawed. In addition they present no data of any kind that allows one skilled in the art to be able select a preferred compound from the large number that are claimed.
~n WO 99/48482 PCT/GB99/00960
The inventors have found that smilagenin (SMI) and anzurogenin D (AZD) exhibit the ability to regulate receptors. In particular, these compounds - and especially SMI — have been found to increase the number of
M2 receptors in the brain. Thus, according to one aspect of the invention, there is provided the use of smilagenin and/or anzurogenin D in the manufacture of a medicament for the treatment of a condition characterised by a deficiency in postsynaptic membrane-bound receptor number or function.
Those skilled in the art will be aware of the relationship between saponins and their sapogenins, and that the desired effects of sapogenins can be exhibited in patients by administration of the corresponding saponins, or a mixture thereof. Hydrolysis of at least a proportion of saponin occurs in the gastrointestinal tract. The skilled man will also be aware of the epimerisation of certain sapogenins under conditions of acid hydrolysis. 15°
The sapogenins of interest in this invention are of the following general formula: = O 25 e~ = (cI) 00 ;
HO gH °
With reference to this general formula, SMI and AZD have the structure indicated in the Table below:
-8~
Compound A/B ring C25 methyl Hydroxyl group(s)
Cis/Trans/ | stereochemistry on a unsaturation (R or S) Spirostane ring
I I
- = Anzurogenin—D Trans 38-0OH, 5a-O0H, ) The saponins and sapogenins of interest in the present invention occur ’ naturally in a range of plant species, notably from the genera Smilax, ) 3 Asparagus, Anemarrhena, Yucca and Agave. The species presently of greatest : - interest include Smilax regelii Kilip & Morton - commonly known as Honduran : 10 - sarsaparilla; Smilax aristolochiaefolia Miller — commonly knownas Mexican - | ) sarsaparilla; Smilax omata Hooker — commonly known as Jamaican sarsaparilla; ’ h Smilax aspera — commonly known as Spanish sarsaparilla; Smilax glabra a i Roxburgh; Smilax febrifuga — Kunth —commonly known as Ecuadorian or
Peruvian sarsaparilla; Anemarrhena asphodeloides Bunge; Yucca schidigera | Roezl ex Ortgies; and Yucca brevifolia Engelm.
According to a further aspect of the present invention, there is provided a pharmaceutical composition having cognitive function enhancing properties which comprises an effective amount of smilagenin and/or anzurogenin D.
In another aspect, the invention provides a pharmaceutical composition having cognitive function enhancing properties which comprises an effective amount of smilagenin and/or anzurogenin D in the form of an extract derived from a plant of the genus Smilax, Asparagus, Anemarrhena, Yucca or Agave.
It will be appreciated that the invention embraces within its scope the use
-g-~ of the compositions defined above. Thus, according to a fifth aspect, the present invention provides a method of enhancing cognitive function which comprises administering to a human or animal an effective dosage of a composition of the invention.
The invention also provides a method of enhancing cognitive function in a human or non-human animal, which comprises administering an effective dose of smilagenin and/or anzurogenin D.
As used herein, the term "cognitive function" refers to functions such as thinking, reasoning, remembering, imagining and learning.
In identifying compounds that would have use in the treatment of SDAT and other diseases characterised by reductions in receptor numbers or synaptic transmission, the inventors have given consideration to the need to identify compounds that would have the desired effect but would be devoid of any oestrogenic effects, as these would be unacceptable, particularly in male patients. A number of the compounds claimed to have activity in patent application DE 4303214A1 have marked oestrogenic activity and are therefore unacceptable. Smilagenin and anzurigenin D, however, do not display oestrogenic activity. In addition these two compounds were tested at other steroid receptors and neither compound was found to have any activity at any of the following receptors:
Progesterone
Glucocorticoid
Testosterone
The selected compounds have also been tested for their activity in a number of in-vitro assays. The assays/experiments that were considered of key importance in determining possible activity in the elevation of membrane bound receptor numbers were as follows: 1. Chinese hamster ovary (CHO) cells transfected with the a DNA fragment : . | ; coding for a muscarinic receptor. The cell line used for the majority of co 5 the experiments was a cell line expressing the m2 receptor. wo 2. The effects of muscarinic receptor expression in cultured cell lines of neuronal origin were investigated. 3. Cultured cardiac muscle cells obtained from neonatal Sprague Dawley rats. The cardiac muscle cells express muscarinic receptors, typically m2. he The level of these receptors falls on prolonged culture and the effects of . a compounds of interest in preventing the fall in receptor numbers was investigated. } 15 SE + : =r The methods and the results of these experiments are now described in tum. 1 CHO cell line experiments
The effects of various compounds on the expression of m2 receptors on CHO cells transfected with DNA for the m2 receptor were investigated. Receptor numbers were assayed using tritiated QNB binding and subtracting non-specific binding. Compounds were dissolved in DMSO and DMSO was used as a control. Compounds were tested at a range of final concentrations. Compounds were also tested in the presence and absence of tamoxifen to try to distinguish an oestrogen receptor mediated mechanism. The results are summarised in the
Table 2 below, where the compounds used in the invention appear in bold, and data on other sapogenins is given for comparative purposes:
A WO 99/48482 PCT/GB99/00960
Table 2 Effects of compounds on the expression of m, receptors on CHO cells
Compound Molar concentration Effect on receptor of compound expression — given as % increase compared to control (negative values in brackets) :
NS = No significant effect
Le »
Thus the experiments indicate that smilagenin and anzurogenin D were able to increase the number of muscarinic receptors expressed on the surface of
CHO cells cultured in-vitro. The effect was not antagonised by tamoxifen, indicating that the mechanism involved did not involve the oestrogen receptor.
SAN : 5 = : 2 Effects of compounds on cell survival = i Other in vitro assays have been employed to establish the effects of smilagenin and anzurogenin D. In particular various neuroblastoma cell lines including
SKN-SN and SH-SY5Y cells as well as phacchromoacytoma cell lines have been cultured in vitro in the presence of f—amyloid fragments or serum depletion. A number of techniques to demonstrate the effectiveness of the - «~~ compounds in protecting the cultured cells were investigated. These techniques included Trypan blue exclusion, chemiluminescence and release of lactate = 15 " dehydrogenase. Of most interest was the observation that incubation of cells, in wo E = particular PC12 cells, with f-amyloid reduced the number of muscarinic 3 receptors measured using radio-labelled ligand binding techniques. This i reduction in receptor numbers was found to be ameliorated by smilagenin and by anzurogenin D. 3 Effects of compounds on cultured cardiac muscle cells.
Cardiac muscle cells were isolated from the ventricular muscle of neonatal
Sprague Dawley rats using standard techniques. Cells were cultured in vitro and muscarinic receptor numbers expressed on cell surfaces membrane fragments after homogenisation of cells harvested at various time points were estimated using specific binding of tritiated QNB. Preliminary experiments demonstrated that the number of receptors expressed tended to decline after 10 days of culture. The experiments were therefore designed to investigate the effects of the various compounds in inhibiting this decline in receptor numbers.
&» Wo99/48482 PCT/GB99/00960
The results of these experiments are summarised in Table 3, where the compounds used in the invention appear in bold, and data on other sapogenins is given for comparative purposes:
Table 3: Effects of various compounds on muscarinic receptor expression on cultured cardiac muscle cells
Compound Concentration of compound causing a significant increase in number of receptors expressed on neonatal cardiac muscle after 10 days in vitro culture :
NS = No significant effect
It is speculated here that the effect of the active compounds claimed in this patent may operate through an effect on G protein and that the effects on receptor numbers are secondary to an effect on G-protein. When a membrane bound G-protein linked receptor is stimulated two basic sets of events are initiated: the effecter response; and the internalisation of the receptor. The subsequent processing of the receptor to the state where it is again in a form on the cell surface or other membrane surface where it can interact with another receptor ligand appears to be subject to a number of factors. A number of these i ~ factors or mechanisms appear to be G-protein linked. There is evidence that activation of m, receptors may have an effect on G-protein expression or levels.
It is speculated that the actions of the compounds described in this patent may © = due to an interaction in the processes of receptor regeneration, G-protein = linkage or G-protein homeostasis. - | An alternative hypothesis is that the compounds are increasing the synthesis or release or a decreased rate of degradation of neurotropic factors : “such as brain derived growth factor and/or nerve growth factor. These effects on growth factors might be due to an effect of the compound on a cytosolic or - nuclear receptor or the binding of a compound to a promoter region with a “15 E consequent effect directly on the rate of production of mRNA for the growth : : “factor or as a consequence of increasing the production of another material factor such as G-protein or finally the effects may be secondary to an effect on : receptor or G-protein procession.
Claims (19)
1. The use of smilagenin in the manufacture of a medicament for the treatment of a condition characterised by a deficiency in membrane-bound receptor number or function.
2. The use of anzurogenin D in the manufacture of a medicament for the treatment of a condition characterised by a deficiency in membrane-bound receptor number or function.
3. A pharmaceutical composition having cognitive function enhancing properties which comprises a pharmacologically effective amount of smilagenin and/or anzurogenin D.
4. A pharmaceutical composition having cognitive function enhancing properties which comprises a pharmacologically effective amount of smilagenin and/or anzurogenin D in the form of an extract derived from a plant of the genus Smilax, Asparagus, Anemarrhena, Yucca or Agave.
5. The use of an effective dosage of a composition as claimed in claim 3 or 4 for preparing a medicament for enhancing cognitive function in a human or animal.
6. A non-therapeutic method of enhancing cognitive function in a human or non-human animal, which comprises administering an effective dose of smilagenin and/or anzurogenin D.
7. The use of a pharmacologically effective dose of smilagenin and/or anzurogenin D for preparing a medicament for enhancing cognitive function in a patient suffering from age-related cognitive disfunction. AMENDED SHEET
PCT/GB99/00960
8. The use as claimed in claim 5 or 7, which is for the treatment of Alzheimer's disease or a senile dementia of the Alzheimer's type.
9. A method as claimed in claim 6, substantially as herein described.
10. A composition for use as claimed in any one of claims 5, 7, 8, or 9, substantially as hereinbefore described.
11. A substance or composition for use in a method for the treatment of a condition characterised by a deficiency in membrane-bound receptor number or function, said substance or composition comprising smilagenin, and said method comprising administering said substance or composition.
12. A substance or composition for use in a method for the treatment of a condition characterised by a deficiency in membrane-bound receptor number or function, said substance or composition comprising anzurogenin D, and said method comprising administering said substance or composition.
13. A substance or composition for use in a method for enhancing cognitive function in a human or animal, said substance or composition comprising a composition as claimed in claim 3 or 4, and said method comprising administering an effective dosage of said substance or composition.
14. A substance or composition for use in a method for enhancing cognitive function in a patient suffering from age-related cognitive disfunction, said substance or composition comprising smilagenin and/or anzurogenin D, and AMENDED SHEET
PCT/GB99/00960 said method comprising administering a pharmacologically effective dose of said substance or composition.
15. A substance or composition for use in a method of treatment according to claim 13 or claim 14, which is for the treatment of Alzheimer's disease or a senile dementia of the Alzheimer's type.
16. Use according to any one of claims 1, 2, 5, or 7, substantially as herein described and illustrated.
17. A composition according to claim 3 or claim 4, substantially as herein described and illustrated.
18. A substance or composition for use in a method of treatment according to any one of claims 11 to 14, substantially as herein described and illustrated.
19. A new use of smilagenin or anzurogenin D, or of a composition as claimed in claim 3 or claim 4; a new composition; a new non-therapeutic method of treatment; or a substance or composition for a new use in a method of treatment; substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806513.9A GB9806513D0 (en) | 1998-03-26 | 1998-03-26 | Membrane-bound receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200006047B true ZA200006047B (en) | 2002-01-28 |
Family
ID=10829328
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200006046A ZA200006046B (en) | 1998-03-26 | 2000-10-26 | Steroidal sapogenins and their derivatives for treating Alzheimer's disease. |
ZA200006047A ZA200006047B (en) | 1998-03-26 | 2000-10-26 | Smilagenin and anzurogenin-D for the treatment of Alzheimer's disease. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200006046A ZA200006046B (en) | 1998-03-26 | 2000-10-26 | Steroidal sapogenins and their derivatives for treating Alzheimer's disease. |
Country Status (3)
Country | Link |
---|---|
GB (1) | GB9806513D0 (en) |
RU (1) | RU2242978C2 (en) |
ZA (2) | ZA200006046B (en) |
-
1998
- 1998-03-26 GB GBGB9806513.9A patent/GB9806513D0/en not_active Ceased
-
1999
- 1999-03-26 RU RU2000126789/14A patent/RU2242978C2/en not_active IP Right Cessation
-
2000
- 2000-10-26 ZA ZA200006046A patent/ZA200006046B/en unknown
- 2000-10-26 ZA ZA200006047A patent/ZA200006047B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2242978C2 (en) | 2004-12-27 |
GB9806513D0 (en) | 1998-05-27 |
ZA200006046B (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1066033B1 (en) | Smilagenin and anzurogenin-d for the treatment of alzheimer's disease | |
US6258386B1 (en) | Smilagenin and its use | |
US7368137B2 (en) | Smilagenin and its use | |
CA2385410C (en) | Sapogenin derivatives and their use in the treatment of cognitive dysfunction | |
EP1224207B1 (en) | 5-hydroxysapogenin derivatives with anti-dementia activity | |
US20030118673A1 (en) | Smilagenin and anzurogenin-D for the treatment of alzheimer's disease | |
ZA200006047B (en) | Smilagenin and anzurogenin-D for the treatment of Alzheimer's disease. | |
AU781810B2 (en) | Steroidal sapogenins and their derivatives for treating Alzheimer's disease | |
CZ20003538A3 (en) | Use of smilagenin and anzurogenin-D for treating Alzheimer's disease | |
MXPA00009441A (en) | Membrane-bound receptors and their function;cognitive disfunction;treatments therefor;and compositions for use in such treatments |